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Objectives: While cilostazol is commonly used as an
adjunct following peripheral vascular interventions (PVI),
its efﬁcacy remains uncertain. We assessed the effect of cil-
ostazol on outcomes following PVI using meta-analytic
techniques.Methods: We searched MEDLINE (1946-2012),
Cochrane CENTRAL (1996-2012), and trial registries
for studies comparing cilostazol in combination with
antiplatelet therapy to antiplatelet therapy alone
following PVI. Treatment effects were reported as
pooled risk/hazard ratios using random effects
models.
Results: Two randomized trials and four retrospec-
tive cohort studies met inclusion criteria (total n ¼
1,522). Across studies, mean age ranged from 66-76
years, the majority of patients were male (59-82%), and
mean follow-up ranged from 18-37 months. Pooled esti-
mates demonstrated that the addition of cilostazol was
associated with decreased restenosis (RR, 0.71; P <
.001; 95% CI, 0.60-0.84), improved amputation-free
survival (HR, 0.63; P ¼ .002; 95% CI, 0.47-0.85),
improved limb salvage (HR, 0.42; P < .001; 95% CI,
0.27-0.66), and improved freedom from target lesion
revascularization (TLR) (RR, 1.36; P < .001; 95% CI,
1.14-1.61) (Fig). There was no signiﬁcant reduction in
mortality among those receiving cilostazol (RR, 0.73; P ¼
.21; 95% CI, 0.45-1.19).
Conclusions: The addition of cilostazol to standard
therapy following PVI is associated with a reduced risk of
restenosis, amputation and TLR in our meta-analysis of
six studies. Consideration of cilostazol as a medical adjunct
after PVI is warranted, presuming these ﬁndings are
broadly generalizable.
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Detrimental Role of Heat Shock Protein 60&70 and
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Objectives: The innate immune response contributes
to the skeletal muscle damage in patients with critical
limb ischaemia (CLI); however, the detailed signalling
mechanisms are not fully understood. We hypothesised
that simulated ischaemia induces inﬂammatory cytokine
release from skeletal myotubes, via a mechanism that
involves heat shock protein (HSP) 60&70, known
endogenous ligands of Toll-like receptor 4 (TLR4), in
vitro.
Methods: Human gastrocnemius muscle biopsies
were taken from patients with CLI undergoing major
lower limb amputation and from patients with no periph-
eral arterial disease (PAD). Human myoblasts were iso-
lated, cultured to myotubes and then pretreated with
TLR4 neutralizing antibody prior to exposure to simulated
ischaemia. Fluorescent immunostaining was carried out to
conﬁrm cell differentiation; ELISA analysis were carried
out to quantify IL6 and TNF-a release; and Western blot
was used to assess expression of HSP60&70, TLR4 and
cleaved caspase-3 as a marker of apoptosis.
Results: Myotubes from patients with CLI expressed
greater levels of cleaved caspase-3 and TLR4 as compared
to those from patients with no PAD. When exposed to
ischaemic conditions, increased IL6 and TNF-a release
and upregulation of HSP60&70, cleaved caspase-3 and
TLR4 were observed in myotubes from both groups of
patients compared to culturing in normoxic conditions
(P < .05). Pretreatment of myotubes from patients withCLI with TLR4 neutralizing antibody prior to simulated
ischaemia was associated with reduced expression of
HSP60&70, IL6, TNF-a and cleaved caspase-3 (P < .05).
Conclusions: Increased cytokine release, apoptosis
and expression of HSP60&70 and TLR4 occur in ischae-
mic skeletal muscle in vitro. TLR4 antagonism was associ-
ated with reduced apoptosis and inﬂammatory cytokine
release and down-regulation of HSP60&70 expression.
Here we report an intimate link between HSP60&70-
induced inﬂammatory cytokine production and TLR4 inhi-
bition in ischaemic human myotubes.
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Loss of Function Studies Highlight the Vasculoprotec-
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Objectives: Transplant arteriosclerosis (TA) is an
accelerated form of atherosclerosis largely driven by the
immune response to the allograft. As for all atherosclerotic
disease, inﬂammation is central to vascular remodeling
associated with TA. We have shown that the potent NF-
kB inhibitory protein A20 exerts atheroprotective effects,
in part through its anti-inﬂammatory and antiapoptotic
functions in endothelial cells (EC), its anti-inﬂammatory,
and anti-proliferative functions in smooth muscles cells
(SMC), and its speciﬁc pro-apoptotic function in neointi-
mal SMC. In this work, we wanted to check the physio-
logic role that A20 plays in the vascular remodeling
associated with transplant arteriosclerosis by performing
loss of function experiments in a mouse model of TA.
Methods: We used a murine vascular transplant
model, implanting aortae of 8-12 week old C57bL/6
mice into the carotid arteries of fully HLA mismatched
Balb/c mice. For our donors, we used aortic grafts from
C57bL/6 A20 heterozygote mice (HET) or from their
wild-type littermates (WT). Aortic allografts were har-
vested after 10 days and 4 weeks.
Results: Partial loss of A20 in aortic allografts caused
signiﬁcantly greater TA lesions, measured by intima over
media ratios in wild type allografts. This was associated
with higher inﬂammation as evaluated by VCAM-1 immu-
nostaining and granulocyte inﬁltration, lower expression of
the anti-inﬂammatory and tolerogenic cytokine IL-10, and
greater incidence of thrombosis in HET allografts.
Conclusions: We conclude that A20 plays an impor-
tant physiologic role in vascular remodeling, and propose
that tailored A20-based vascular therapies could decrease
incidence and severity of TA, and synergize with or mini-
mize use of immunosuppression in solid organ transplanta-
tion. These results are particularly relevant to newly
discovered A20 single nucleotide polymorphisms that are
less effective in inhibiting inﬂammation, and have been
